Biote Corp. BTMD
Institutional shares held
17.7 Million
0
calls
0
puts
Total value of holdings
$107M
$0
calls
$0
puts
Market Cap
$45.7M
7,574,270
Shares Out.
Institutional ownership
233.62%
# of Institutions
83
We take great care to ensure that the data presented and summarized in this overview for biote Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BTMD
View all-
325 Capital LLC New York, NY4.55MShares$27.5 Million13.05% of portfolio
-
Bandera Partners LLC New York, NY2.44MShares$14.7 Million5.13% of portfolio
-
Black Rock Inc. New York, NY1.61MShares$9.69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$8.56 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.39MShares$8.41 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX678KShares$4.1 Million0.0% of portfolio
-
Boston Partners Boston, MA615KShares$3.72 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA559KShares$3.38 Million0.0% of portfolio
-
Sw Investment Management LLC Chicago, IL500KShares$3.02 Million0.74% of portfolio
-
State Street Corp Boston, MA475KShares$2.87 Million0.0% of portfolio
Latest Institutional Activity in BTMD
Top Purchases
Top Sells
About BTMD
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Insider Transactions at BTMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2024
|
Robert Charles Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,874
-100.0%
|
$197,244
$6.2 P/Share
|
|
Jul 09
2024
|
Robert Charles Peterson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,376
-25.71%
|
$79,632
$7.57 P/Share
|
|
Jul 08
2024
|
Robert Charles Peterson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,250
+50.0%
|
-
|
|
May 21
2024
|
Debra L Morris |
BUY
Exercise of conversion of derivative security
|
Direct |
9,110
+18.89%
|
-
|
|
May 21
2024
|
Dana Lynn Jacoby |
BUY
Exercise of conversion of derivative security
|
Direct |
11,595
+18.53%
|
-
|
|
Jul 05
2023
|
Mary Elizabeth Conlon General Counsel |
SELL
Open market or private sale
|
Direct |
6,240
-4.26%
|
$37,440
$6.5 P/Share
|
|
Jun 30
2023
|
Dana Lynn Jacoby |
BUY
Exercise of conversion of derivative security
|
Direct |
6,058
+13.33%
|
-
|
|
Jun 30
2023
|
Stephen Mark Cone |
BUY
Exercise of conversion of derivative security
|
Direct |
6,058
+4.7%
|
-
|
|
Jun 30
2023
|
Mary Elizabeth Conlon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
24,231
+14.18%
|
-
|
|
Jun 09
2023
|
Roystone Capital Management LP > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
99,372
+3.13%
|
-
|
|
Apr 04
2023
|
Mary Elizabeth Conlon General Counsel |
SELL
Open market or private sale
|
Direct |
10,867
-8.15%
|
$54,335
$5.92 P/Share
|
|
Mar 31
2023
|
Stephen Mark Cone |
BUY
Exercise of conversion of derivative security
|
Direct |
9,844
+7.78%
|
-
|
|
Mar 31
2023
|
Dana Lynn Jacoby |
BUY
Exercise of conversion of derivative security
|
Direct |
9,844
+22.81%
|
-
|
|
Mar 31
2023
|
Mary Elizabeth Conlon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+22.81%
|
-
|
|
Feb 07
2023
|
Roystone Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
375,000
+11.21%
|
$1,125,000
$3.25 P/Share
|
|
Jan 09
2023
|
Stephen Mark Cone |
BUY
Open market or private purchase
|
Direct |
83,350
+43.83%
|
$250,050
$3.0 P/Share
|
|
Jan 09
2023
|
Debra L Morris |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$90,000
$3.0 P/Share
|
|
Jan 09
2023
|
Samar Jagat Kamdar Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
13,000
+50.0%
|
$39,000
$3.0 P/Share
|
|
Jan 09
2023
|
Teresa Sue Weber Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
865,384
-91.05%
|
$2,596,152
$3.0 P/Share
|
|
Jan 09
2023
|
Marc D Beer |
SELL
Open market or private sale
|
Direct |
865,384
-100.0%
|
$2,596,152
$3.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
65K
Shares
From
3
Insiders
| Exercise of conversion of derivative security | 65K shares |
|---|
Sell / Disposition
44.3K
Shares
From
1
Insiders
| Open market or private sale | 44.3K shares |
|---|